CURRENT RECRUITING TRIALS

For information on Brain Tumour clinical trials, please contact
bt-cru.neuro@mcgill.ca.

AGILE (Glioblastoma)

GBM AGILE: An international, seamless phase II/III response adaptive randomization platform trial designed to evaluate multiple regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM)

From clinicaltrials.gov

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.

More information

INTRAGO II (Glioblastoma)

A Multicenter, Randomized Phase III Study on Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma multiforme:–>

From clinicaltrials.gov:

INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.

More information

THE TEAM

Dr. Kevin Petrecca

Dr. Kevin Petrecca

Principal Investigator

Mostafa Ghozlan

Mostafa Ghozlan

Team Lead

THE TEAM

Dr. Scott Owen

Dr. Scott Owen

Principal Investigator

Luciano Buonamici

Luciano Buonamici

Research Coord.

UPCOMING TRIALS

To come

ACTIVE (NOT RECRUITING) TRIALS

ORBUS (Astrocytoma)

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.

This study will consist of 4 study periods of up to 50 months in total, consisting of:Screening Period – A maximum screening duration of 4 weeks.

Treatment Period – Treatment Arm A up to 24 months; Treatment Arm B up to 12 months.

End of Treatment Visit – A minimum of 4 weeks post last treatment for both arms.

Follow-Up Period – Up to 24 months.

A total of approximately 280 patients will be randomized in a 1:1 ratio to receive either eflornithine + lomustine or lomustine alone.

More information